Tenders Are Invited For Mass Spectrometer – Massenspektrometer

Mass Spectrometer – Massenspektrometer. Newborn Screening (Ngs) Is Carried Out On All Newborns Throughout Germany (>99%). It Is Used For The Early Detection Of Congenital Metabolic, Hormonal, Blood, Immune And Neuromuscular Diseases, As Well As Cystic Fibrosis In Newborns. The Aim Is To Detect The Diseases Early, Before They Lead To Serious Damage, Disabilities Or Even Death, And To Initiate Timely Treatment. Policy Change 05/2025 The Last Change To The Childrens Policy Was Decided On May 15, 2025. The Screening Portfolio Will Be Expanded From 16 Diseases To Include 4 Additional Diseases: 17. Vitamin B12 Deficiency, 18. Homocystinuria, 19. Propionic Acidemia, 20. Methylmalonic Aciduria In May Next Year. Successful Implementation Of These Specific Requirements Can Only Be Achieved If There Is Sufficient Measurement Time On The Mass Spectrometers (Ms). Since The Rapid Processing Of Samples In Ngs Is Essential, All Analytical Methods Must Be Available In Sufficient Numbers. The Two Current Mss Are Fully Utilized By The Daily Routine Analysis Of The Ngs As Well As By The Provision Of The Previous Second-Tier Methods Of The Ngs As Well As Other Parameters Of The Central Laboratories. In Order To Do Justice To The G-Bas Innovations, Newborn Screening Therefore Needs Another Mass Spectrometer As Quickly As Possible.